Epigenomics AG (ECX)
XSTU 
Summary
ECX Chart
Epigenomics AG (ECX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Epigenomics AG ever had a stock split?
Epigenomics AG Profile
| Professional Services Industry | Industrials Sector | Jason Wouhra CEO | XSTU Exchange | DE000A3H2184 ISIN |
| DE Country | 3 Employees | - Last Dividend | 8 Dec 2023 Last Split | - IPO Date |
Overview
Epigenomics AG is a pioneering molecular diagnostics company with a specialized focus on the development of liquid biopsy tests designed for the early detection of cancer. Founded in 1998 and based in Berlin, Germany, Epigenomics AG endeavors to combat cancer through its innovative testing solutions, making early detection more accessible to patients worldwide. Leveraging the power of cutting-edge science, the company seeks to identify crucial biomarkers in human tissue, aiming to develop and patent corresponding in vitro diagnostic blood tests that can significantly impact cancer diagnosis and treatment strategies. Through its commitment to research and development, Epigenomics AG is at the forefront of providing groundbreaking diagnostic tools that contribute to the global fight against cancer.
Products and Services
- Epi proColon
Epi proColon stands as Epigenomics AG's flagship product, marking a significant advancement in the field of non-invasive cancer diagnostics. This blood-based test is specifically designed for the early detection of colorectal cancer, one of the most common and lethal forms of cancer worldwide. Available in the United States, Europe, and China, Epi proColon offers a convenient and less invasive alternative to traditional colorectal screening methods, such as colonoscopy. By simplifying the early detection process, Epigenomics AG aims to encourage higher screening rates, potentially saving lives through early intervention.
- Epi BiSKit
The Epi BiSKit from Epigenomics AG is a pre-analytical tool that provides a comprehensive set of reagents essential for the preparation of bisulfite-converted DNA. This kit is crucial in the process of detecting DNA methylation, an important epigenetic change that occurs in the genome of cancer cells. By offering Epi BiSKit, Epigenomics AG facilitates the research and development efforts of scientists and clinicians focusing on cancer diagnostics, thus supporting the broader application and validation of liquid biopsy tests in clinical settings.
